CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
CASI Pharmaceuticals, Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$0.10+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns CASI Pharmaceuticals's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Quan Zhou | 992,638 | 6.40% | 13D (active) amendment | Dec 30, 2024 |
| Foresite Capital Management VI, LLC | 787,121 | 5.10% | 13G (passive) amendment | Jun 30, 2025 |
| James Huang | 4,651,527 | 22.50% | 13D (active) amendment | Dec 16, 2025 |
| WEI-WU HE, Ph.D. | 23,985,535 | 58.80% | 13D (active) amendment | May 18, 2026 |
| Chen Zhenfeng | 2,255,636 | 11.00% | 13G (passive) | Sep 30, 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 1,987,259 | 9.20% | 13G (passive) amendment | Dec 31, 2025 |
| Jingbo Wang | 1,019,852 | 5.00% | 13D (active) amendment | Sep 30, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Wei R. Gao | General Counsel | – | – | Apr 16, 2026 |
| Kun Qian | Global Controller | – | – | Apr 13, 2026 |
| Hai Huang | Global Chief Commercial Ofcr | – | – | Apr 7, 2026 |
| Chunhua Wang | Chief Operating Officer | – | – | Apr 3, 2026 |
| Alexander A. Zukiwski | Global Chief Medical Officer | – | – | Apr 3, 2026 |
| Thomas Folinsbee | Director | – | – | Apr 23, 2026 |
| Xuebo Zeng | Director | – | – | Apr 20, 2026 |
| Barbara Helene Hannelore Krebs-Pohl | Director | – | – | Mar 27, 2026 |
| Alex Wu | Director | 34,168 | 0.17% | Mar 25, 2026 |
| James Huang | Director | 4,529,956 | 22.04% | Mar 18, 2026 |
| Wei-Wu He | Director, 10% owner | 2,592,301 | 12.61% | Mar 18, 2026 |
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Innovation Ltd Panacea Owner | Mar 15, 2024 | 171,000 | $534.19K | Mar 15, 2024 | Open Market Purchase |
| Innovation Ltd Panacea Owner | Mar 5, 2024 | 134,000 | $925.94K | Mar 5, 2024 | Open Market Purchase |